| | | EXHIBIT 99.01 |
| | Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com |  |
| | | |
| | Press Release | |
28 September 2005
Shire Pharmaceuticals Group plc (the “Company”)Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities
The Company announces that on 28 September 2005 it was notified of the exercise in London on the same day by Mr Gregory Flexter, Executive Vice President and General Manager, North America, of an option over 86,466 ordinary 5p shares in the Company at an exercise price of £5.25.
The Company further announces that on 28 September 2005 it was notified of the sale in London on the same day by Mr Flexter of the same 86,466 ordinary 5p shares in the Company at a price of £6.92.
Following these transactions, Mr Flexter holds options over 447,088 ordinary 5p shares in the Company.
For further information please contact:
| Investor Relations | | Cléa Rosenfeld (Rest of the World) | | +44 1256 894 160 |
| | Brian Piper (North America) | | +1 484 595 8252 |
Notes to editors
Shire Pharmaceuticals Group plc
Registered in England 2883758 Registered Office as above
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), renal diseases and human genetics. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company’s website:www.shire.com.
